Fina signs licensing deal for pneumococcal conjugate vaccines
Under the terms of the agreement, Fina will receive an upfront payment, payments based on the achievement of the CDIBP reaching regulatory milestones, and royalty payments contingent upon successful commercialization and development, Pharmaceutical Business Review reports.
"Our expertise in bioconjugation allows vaccines to be manufactured at lower costs than traditional methods, which ultimately allows for greater uptake into developing economies and in turn benefits all of humanity," Andrew Lees, the CEO and scientific director of Fina Biosolutions, said, according to Pharmaceutical Business Review.
The agreement also makes provisions for process development, personnel training at Fina Biosolutions' laboratories in Rockville and the scalable manufacturing of conjugate vaccines at the CDIBP.
"We are pleased to have entered into a development agreement with Fina, an innovative company that has world class expertise in conjugate vaccines," Yonghong Ge, a CDIBP representative, said. "The technology is already proven in marketed vaccines Synflorix, Menitorix, Nimenrix and sold by GlaxoSmithKline. This vaccine, if successful, has the potential to benefit over 330 million people in China alone."
Worldwide, pneumonia is the leading killer of children under the age of five, according to the World Health Organization.